Synonyms: 1,11-anhydro[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl- N-methyl-L-valyl-[(2S,3R,4R,6E)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2S)-2-aminobutanoyl]- N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine] | E-ISA247 | ISA(TX)247 | ISA-247 | ISA247 | ISATX247 | Lupkynis® | R 1524 | R-1524 | R1524
voclosporin is an approved drug (FDA (2021), EMA (2022))
Compound class:
Peptide
Comment: Voclosporin (ISA247, ISATX247) is a cyclic peptide that is a semi-synthetic cyclosporine analogue [1-3,6], but with distinct clinical efficacy and safety profiles [5]. Like cyclosporine, it has immunosuppressive action, and it binds cyclophilin A [4]. Functionally, it acts as a calcineurin inhibitor. Prior to voclosporin, clinically used calcineurin inhibitors were cyclosporine (cyclosporin A), tacrolimus, and pimecrolimus.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use |
Voclosporin was advanced to clinical evaluation for autoimmune diseases and the prevention of organ graft rejection. The FDA approved voclosporin (Lupkynis®) in January 2021, as an adjunctive treatment for active lupus nephritis, to be used in combination with a background immunosuppressive therapy. In the EU voclosporin was granted orphan designation (December 2012) as a treatment for non-infectious uveitis. |
Mechanism Of Action and Pharmacodynamic Effects |
Calcineurin is a phosphatase that is a key component of immune signalling and which regulates the action of cytotoxic lymphocytes. Drugs that (indirectly) inhibit calcineurin block T cell proliferation and thereby generate their immunosuppressive action. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00244842 | Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis | Phase 3 Interventional | Aurinia Pharmaceuticals Inc. | ||
NCT03597464 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin | Phase 3 Interventional | Aurinia Pharmaceuticals Inc. | ||
NCT03021499 | Aurinia Renal Response in Active Lupus With Voclosporin | Phase 3 Interventional | Aurinia Pharmaceuticals Inc. |